FDAnews Drug Daily Bulletin

ROCHE SIGNS TECHNOLOGY DEAL WITH US-BASED AMBRX

Dec. 9, 2005
A A

Roche Holding AG said it has signed an agreement with Ambrx Inc giving it access to the US's company's technology to develop 'next generation' proteins and peptides that offer efficacy or safety advantages over existing products. 'If proven successful, Ambrx's technology could potentially be beneficial to multiple projects in our biologics pipeline,' the Swiss drugmaker said.

Forbes (http://www.forbes.com/business/feeds/afx/2005/12/08/afx2377352.html)